Displaying drugs 11451 - 11475 of 11650 in total
Natural Killer Cell
Natural Killer (NK) cells originate and differentiate from hematopoietic stem cells through various signalling pathways involving cytokines and interleukins. These cells arise from CD34+ lymphoid progenitors and comprise 10-15% of all lymphocytes in human peripheral blood. Once completely differentiated, NK cells lack B (CD19-) and T(CD3-) lymphocyte markers and carry...
Investigational
Matched Description: … leukapheresis: a technique where immune cells are separated from red blood cells. ... The most standard and utilized source of NK cells is directly from the peripheral blood of a donor through ... stem cells (iPSCs) and human embryonic stem cells (HESCs) are also used to generate NK cells through a …
TA-NIC
TA-NIC is a novel and proprietary vaccine in development as an aid to quitting smoking in motivated patients. It is designed to raise anti-nicotine antibodies which bind to nicotine molecules in the patient's blood stream, reducing the rate and quantity of nicotine entry into the brain, to reduce the addictive...
Investigational
Matched Description: … TA-NIC is a novel and proprietary vaccine in development as an aid to quitting smoking in motivated patients …
PMI-001
PMI-001 is a stand-alone, disease-modifying, anti-rheumatic drug (DMARD) being developed by Phytomedics Inc. It is an extract of the roots of an undisclosed perennial shrub which interferes with the production of IL-2 and COX-2 proteins, for the potential treatment of autoimmune diseases, such as rheumatoid arthritis, lupus erythematosus and psoriasis.
Investigational
Matched Description: … PMI-001 is a stand-alone, disease-modifying, anti-rheumatic drug (DMARD) being developed by Phytomedics …
Iproclozide
Iproclozide is an irreversible and selective hydrazine class based monoamine oxidase inhibitor (MAOI). Although it was employed as an antidepressant for a time, the fact that the agent is capable of causing fulminant hepatitis and that its use has been documented as the cause for at least three reported fatalities...
Withdrawn
Matched Description: … Although it was employed as an antidepressant for a time, the fact that the agent is capable of causing …
Sage oil
Sage oil is extracted from sage or Salvia officinalis, the herb commonly used for culinary purposes. Salvia officinalis is a common sage and a member of the genus Salvia, that includes aromatic and perennial plants with flowers. Essential oil has been traditionally used in medicine for the relief of pain...
Nutraceutical
Matched Description: … *Salvia officinalis* is a common sage and a member of the genus *Salvia*, that includes aromatic and …
CVT-6883
CVT-6883 is a selective, potent and orally available A2B-adenosine receptor antagonist which CV Therapeutics is investigating for the potential treatment of asthma and other conditions related to inflammation and fibrosis.
Investigational
Matched Description: … CVT-6883 is a selective, potent and orally available A2B-adenosine receptor antagonist which CV Therapeutics …
Clobutinol
Clobutinol is a cough suppressant that is withdrawn from the US and EU markets. Clobutinol may prolong the QT interval. In 2007, Clobutinol was determined to cause cardiac arrhythmia in some patients.
Withdrawn
Matched Description: … Clobutinol is a cough suppressant that is withdrawn from the US and EU markets. …
Molibresib
Molibresib is under investigation in clinical trial NCT01943851 (A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies).
Investigational
Matched Description: … Molibresib is under investigation in clinical trial NCT01943851 (A Dose Escalation Study to Investigate …
Olmutinib
Olmutinib is an orally active epidermal growth factor receptor inhibitor used in the treatment of T790M mutation positive non-small cell lung cancer. It is available under the brand name Olita made by Hanmi Pharmaceuticals . Olmutinib was developed by Hanmi Pharmaceuticals and Boehringer Ingelheim. Olmutinib recieved breakthrough therapy designation in...
Investigational
PDPSC18
PDPSC18 is therapeutic DNA vaccine designed to fight chronic infections with the Hepatitis B virus, entering phase I clinical trials.
Investigational
MBO7133
MB07133 is a HepDirect prodrug of an activated form of cytarabine (araC), an anti-cancer drug that is used to treat leukemia but is ineffective against primary liver cancer. AraC's anti-cancer activity is associated with its ability to be converted to its biologically active form, araCTP. However, araC is only slowly...
Investigational
Matched Description: … MB07133 is a HepDirect prodrug of an activated form of cytarabine (araC), an anti-cancer drug that is ... MB07133 uses our HepDirect technology to target a prodrug form of araCMP specifically to the liver. …
PF-04995274
Pf 04995274 is under investigation in clinical trial NCT01193062 (Study In Healthy Subjects To Evaluate The Changes In The Protein sAPP-Alpha In Cerebrospinal Fluid Following A Single Oral Dose Of PF-04995274).
Investigational
Matched Description: … Healthy Subjects To Evaluate The Changes In The Protein sAPP-Alpha In Cerebrospinal Fluid Following A …
Rilematovir
Rilematovir is under investigation in clinical trial NCT04056611 (Effects of JNJ-53718678 in Adult and Adolescent Participants Who Had a Hematopoietic Stem Cell Transplantation and Who Are Infected With Respiratory Syncytial Virus (RSV)).
Investigational
Matched Description: … in clinical trial NCT04056611 (Effects of JNJ-53718678 in Adult and Adolescent Participants Who Had a …
RVT-3101
RVT-3101 is a fully human monoclonal antibody targeting vascular endothelial growth inhibitor, also known as TNF-like ligand 1A (TL1A) and TNF superfamily member 15. It is being investigated for ulcerative colitis.
Investigational
Matched Description: … RVT-3101 is a fully human monoclonal antibody targeting vascular endothelial growth inhibitor, also known …
R1626
R1626 is one of a new class of hepatitis C therapies called polymerase inhibitors. It achieves significant reductions in viral load in chronic hepatitis C patients infected with the difficult to treat genotype 1 virus. R1626 is very effective in inhibiting viral replication
Investigational
Matched Description: … R1626 is one of a new class of hepatitis C therapies called polymerase inhibitors. …
Rilapladib
Rilapladib is the third genomics-derived small molecule drug arising from the Human Genome Sciences-GlaxoSmithKline collaboration to enter clinical development. It is a lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor. Lp-PLA2 is an enzyme associated with the formation of atherosclerotic plaques.
Investigational
Matched Description: … It is a lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor. …
Seproxetine
Seproxetine is also known as (S)-norfluoxetine. It is a selective serotonin reuptake inhibitor (SSRI). It is an active metabolite of fluoxetine. Seproxetine was being investigated by Eli Lilly as an antidepressant but development was never completed and the drug was never marketed.
Investigational
Matched Description: … It is a selective serotonin reuptake inhibitor (SSRI). It is an active metabolite of fluoxetine. …
Benactyzine
Benactyzine is an anticholinergic drug used as an antidepressant in the treatment of depression and associated anxiety.
Benactyzine is no longer widely used in medicine, although it is still a useful drug for scientific research. It does not possess any antihistamine properties.
Withdrawn
Matched Description: … Benactyzine is no longer widely used in medicine, although it is still a useful drug for scientific research …
EGT-301
EGT-301 is a gene therapy being investigated for Hunter Syndrome. It consists of an adeno-associated viral vector serotype 9 (AAV9) containing the human Iduronate-2-sulfatase (I2S) transgene designed to restore I2S functional deficiency in patients with Hunter syndrome.
Investigational
Matched Description: … EGT-301 is a gene therapy being investigated for Hunter Syndrome. …
Umbilical Cord Blood Hematopoietic Stem Cells
The use of umbilical cord blood (UCB) for therapies is advantageous because of its ease of access, non-invasive collection procedures, and more plasticity for multi-differentiation. UCB contains a large source of hematopoietic stem cells (HSCs) that are capable of self-renewal, have increased sensitivity to various factors, and are able to...
Investigational
Matched Description: … UCB contains a large source of hematopoietic stem cells (HSCs) that are capable of self-renewal, have …
Razuprotafib
Razuprotafib, also known as AKB-9778, is a small-molecule inhibitor restoring Tie2 activation by inhibiting VE-PTP.[L27171,L27176] In investigations against diabetes and COVID-19, razuprotafib is self-administered by patients through subcutaneous injection.
Investigational
Matched Description: … Razuprotafib, also known as AKB-9778, is a small-molecule inhibitor restoring Tie2 activation by inhibiting …
MP4
MP4 is a hemoglobin-based oxygen carrier designed to serve as an alternative for blood transfusions. It is free of harmful vasoactivity and provides targeted oxygen delivery to tissues at risk of oxygen deprivation.
Investigational
Matched Description: … MP4 is a hemoglobin-based oxygen carrier designed to serve as an alternative for blood transfusions. …
BMS-986104
BMS-986104 is under investigation in clinical trial NCT02211469 (A Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986104 in Healthy Male Subjects).
Investigational
Matched Description: … BMS-986104 is under investigation in clinical trial NCT02211469 (A Randomized, Placebo-Controlled, Double-Blind …
Ontuxizumab
Ontuxizumab is a humanized monoclonal antibody that targets endosialin or tumour endothelial marker 1 (TEM-1). It is under investigation in clinical trial NCT01574716 (Sarcoma Study of Morab-004 Utilization: Research and Clinical Evaluation).
Investigational
Matched Description: … Ontuxizumab is a humanized monoclonal antibody that targets endosialin or tumour endothelial marker 1 …
Cry5B
Cry5B is a pore-forming crystal protein produced by and derived from the soil bacterium Bacillus thuringiensis. With demonstrated anthelmintic properties, it has been investigated in the treatment of parasitic intestinal infections.[A259372, A259377]
Investigational
Matched Description: … Cry5B is a pore-forming crystal protein produced by and derived from the soil bacterium _Bacillus thuringiensis …
Displaying drugs 11451 - 11475 of 11650 in total